595 Biomarker results from the 1st line non-small cell lung cancer cohort of TACTI-002: pharmacodynamic effects of combining eftilagimod alpha (soluble LAG-3) and pembrolizumab

• Enriqueta Felip,
• Christian Mueller,
• Martin Forster,
• Tim Clay,
• Matthew Krebs,
• Frederic Triebel,
• Enric Carcereny,
• Ewa Kalinka,
• Margarita Majem,
• Bernard Doger,
• Julio Peguero,
• Chrystelle Brignone,
• Igor Bondarenko,
• Wade T Iams,
• Manuel Cobo Dols,
• Grygorii Ursol,
• Gema Garcia Ledo,
• Laia Vilà Martinez

Affiliations

Enriqueta Felip

Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Christian Mueller

1 Cardiovascular Research Institute Basel (CRIB), University Hospital Basel, Basel, Switzerland

Martin Forster

1UCL/University College London NHS, London, UK

Tim Clay

6St John of God Subiaco Hospital, Perth, Australia

Matthew Krebs

Division of Cancer Sciences, The University of Manchester, Manchester, UK

Frederic Triebel

13Immutep, Berlin, Germany

Enric Carcereny

7Institut Català d’Oncologia Badalona, Badalona, Spain

Ewa Kalinka

11Instytut Centrum Zdrowia Matki Polki, Lodz, Poland

Margarita Majem

Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Bernard Doger

5Fundacion Jimenez Díaz, Madrid, Spain

Julio Peguero

8Oncology Consultants, P.A., Houston, Texas, USA

Chrystelle Brignone

17Immutep S.A.S., Chatenay-Malabry, France

Igor Bondarenko

12Oncology and Medical Radiology Department, Dnipro State Medical University, Dnipro, Ukraine

Wade T Iams

9Vanderbilt University Medical Center, Nashville, TN, USA

Manuel Cobo Dols

9Regional and Virgen de la Victoria University Hospitals, IBIMA, Malaga, Spain

Grygorii Ursol

10St. Luke’s Hospital – Medical and Diagnostic Center ‘Acinus’’, Kropyvnytskyi, Ukraine

Gema Garcia Ledo

12HM Universitario Sanchinarro, Madrid, Spain

Laia Vilà Martinez

13Parc Taulí Sabadell Hospital Universitari, Barcelona, Spain